Antitumor Effect of a Biological Response Modifier, PSK, on C57BL/6 Mice with Syngeneic Melanoma B16 and Its Mode of Action

Oncology ◽  
1994 ◽  
Vol 51 (4) ◽  
pp. 303-308 ◽  
Author(s):  
Kenichi Matsunaga ◽  
Mika Aota ◽  
Yuko Nyunoya ◽  
Mitsunori Hakozaki ◽  
Yoshiaki Ishikawa ◽  
...  
Keyword(s):  
Mode Of Action ◽  
Antitumor Effect ◽  
Biological Response ◽  
Biological Response Modifier ◽  
Response Modifier ◽  
Melanoma B16

scholarly journals Clinical Development of Biological Response Modifiers

1994 ◽  
Vol 5 (suppl a) ◽  
pp. 5A-8A
Author(s):  
Jay P Siegel
Keyword(s):  
Adverse Reactions ◽  
Biological Response ◽  
Clinical Trial Design ◽  
The United States ◽  
Biological Response Modifier ◽  
Clinical Development ◽  
Response Modifier ◽  
United States Food ◽  
Study Population ◽  
States Food

OBJECTIVE: To present perspectives on selected issues that frequently arise during the clinical development of biological response modifier (BRM) therapies.DATA SOURCES: The perspectives and opinions presented herein were developed over several years of reviewing and consulting on the clinical development of BRM therapies at the United States Food and Drug Administration.CONCLUSIONS: BRM therapies encompass a broad spectrum of products used to treat a wide variety of diseases. Due to this diversity. most principles of clinical trial design and conduct applicable to the majority of BRMS are those that are applicable to all therapies. Nevertheless, the clinical development of BRM therapies often raises specific issues and problems in the areas of selecting animal models, defining the study population, adverse reactions, dosing and defining end-points. Over 10 years’ experience in testing biotechnology derived BRMS in clinical trials has created a database from which we can draw valuable generalizations for guidance in future studies.

Inositol-C2-PAF acts as a biological response modifier and antagonizes cancer-relevant processes in mammary carcinoma cells

2018 ◽  
Vol 41 (5) ◽  
pp. 505-516 ◽  
Author(s):  
Carsten Pelz ◽  
Sonja Häckel ◽  
Geo Semini ◽  
Sandra Schrötter ◽  
Willem Bintig ◽  
...  
Keyword(s):  
Mammary Carcinoma ◽  
Biological Response ◽  
Biological Response Modifier ◽  
Carcinoma Cells ◽  
Response Modifier ◽  
Mammary Carcinoma Cells

Development of a water-soluble, sulfated (1 → 3)-β-d-glucan biological response modifier derived from Saccharomyces cerevisiae

1992 ◽  
Vol 235 ◽  
pp. 247-257 ◽  
Author(s):  
David L. Williams ◽  
Henry A. Pretus ◽  
Rose B. McNamee ◽  
Ernest L. Jones ◽  
Harry E. Ensley ◽  
...  
Keyword(s):  
Saccharomyces Cerevisiae ◽  
Biological Response ◽  
Biological Response Modifier ◽  
Water Soluble ◽  
Response Modifier

scholarly journals Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer

BMC Cancer ◽  
2004 ◽  
Vol 4 (1) ◽  
Author(s):  
Christian Sänger ◽  
Andreas Busche ◽  
Gabriele Bentien ◽  
Ralf Spallek ◽  
Fatima Jonas ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Mycobacterium Tuberculosis ◽  
Biological Response ◽  
Biological Response Modifier ◽  
Response Modifier
Sign in / Sign up

Export Citation Format

Share Document